Global uncertainty puts big central banks in a tight spot
LONDON (Reuters) -Central banks are grappling with elevated uncertainty about economic growth and inflation, complicating decision-making, especially for those trying to calibrate policy as they near the end of their rate-cutting cycles.
That's making life hard for investors too. Norway's central bank on Thursday gave markets a shock by cutting interest rates, and even the U.S. Federal Reserve is warning not to put much weight on its policy projections.
1/ SWITZERLAND
The Swiss National Bank cut its benchmark rate to 0% on Thursday, in response, it said, to falling inflation, a stronger Swiss franc and economic uncertainty caused by unpredictable U.S. trade policy.
The big question is whether it will cut rates into negative territory next time. The SNB is keeping all options on the table, but chairman Martin Schlegel says the hurdle to further cuts is higher now rates are at zero.
2/ CANADA
The Bank of Canada held rates at 2.75% in early June and said another cut might be necessary if the economy weakened in the face of tariffs.
That pause was the second in succession for the BoC, after an aggressive cutting cycle which shrank rates by 225 basis points over nine months. Markets anticipate one further 25 bps cut by year-end.
3/ SWEDEN
Sweden's central bank cut its key rate to 2% from 2.25% on Wednesday and said that, with price pressures weak, it may ease further before year-end to boost sluggish growth.
The Riksbank has been one of the more aggressive central banks, with 200 bps of cuts since May 2024.
4/ NEW ZEALAND
Markets expect the Reserve Bank of New Zealand to hold steady on July 9 after a 25 bps rate cut to 3.25% in May to protect the China-focused economy.
The RBNZ also warned that global trade uncertainties made future moves unclear. Markets see one more 25 bps cut this year, on top of the 225 bps of cuts already this cycle.
5/ EURO ZONE
The ECB cut rates earlier this month, its eighth cut since mid-2024, and kept all options on the table for its next meetings.
ECB President Christine Lagarde says the euro zone central bank's 2% inflation target is in reach. The question for investors is whether inflation will undershoot that target, and necessitate further easing.
Markets price in one more rate cut by year-end.
6/ UNITED STATES
The Federal Reserve held rates steady on Wednesday and signalled borrowing costs are still likely to fall in 2025, although Chair Jerome Powell warned against putting too much weight on that projection.
"No one holds these ... rate paths with a great deal of conviction, and everyone would agree that they're all going to be data-dependent," Powell said.
He added that if not for tariffs, rate cuts might be in order given recent inflation readings have been low.
Markets still see roughly two 25 bps cuts by year-end.
7/ BRITAIN
The sometimes surprising Bank of England met market expectations on Thursday, keeping interest rates at 4.25%.
The BoE has been cutting roughly once a quarter for the past year, and markets expect it to continue at that pace, with two more cuts priced in by year end.
Three of the nine rate-setters voted on Thursday for a cut however. Some investors speculate softening labour data could cause the BoE to up the pace of cuts, though others reckon it will be held back by high UK inflation.
8/ AUSTRALIA
Weak growth data and fears commodities producers and miners will take a blow from a U.S.-China trade war means the Reserve Bank of Australia stands ready to deliver rapid rate cuts.
The RBA cut rates by 25 bps to 3.85% in May and traders see borrowing costs dropping to near 3% by year-end.
9/ NORWAY
Norway's central bank cut its policy interest rate by 25 bps to 4.25% on Thursday, its first reduction since 2020, a decision that took most analysts by surprise and weakened the currency.
The Norges Bank has been the most cautious among developed market central banks on rate cuts, and governor Ida Bache said only one or two more reductions were planned this year.
10/ JAPAN
The Bank of Japan, the sole central bank in hiking mode, kept rates steady on Tuesday, as expected by investors.
Escalating Middle East tensions and U.S. tariffs complicate the BOJ's task of raising still-low interest rates and reducing a balance sheet that has ballooned to roughly the size of Japan's economy.
On Tuesday it decided to decelerate the pace of its balance sheet drawdown next year, signalling its preference to move cautiously in removing remnants of its decade-long stimulus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE
SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a first-in-human (FIH) clinical study of JSKN022 for the treatment of advanced malignant solid tumors. JSKN022 is an innovative bispecific ADC developed in-house with Alphamab's proprietary glycan-specific conjugation platform. The molecule simultaneously targets and binds to both PD-L1 and integrin αvβ6 on the surface of tumor cells. After binding to either target, JSKN022 enters the lysosome through target-mediated endocytosis. The cleavable linker is specifically hydrolyzed by proteolytic enzymes such as cathepsin B, releasing cytotoxic topoisomerase I inhibitor (T01), which then induces apoptosis of PD-L1 and/or integrin αvβ6 positive tumor cells. In addition, the inhibitor can penetrate the cell membrane and enter the antigen-negative tumor cells to exert bystander effects. These combined effects can effectively inhibit the growth of tumor cells. At present, no ADC targeting integrin αvβ6 or PD-L1 has been approved for marketing worldwide, with all related investigational candidates remaining in clinical development stages. Preclinical data demonstrate that JSKN022 exhibits potent antitumor activity in both in vitro and in vivo models against tumor cells expressing integrin αvβ6 and/or PD-L1. JSKN022 will potentially bring in novelty in the therapeutic approach for cancers that are refractory or resistant to PD-1/PD-L1 inhibitors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer. This Phase I clinical study will evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and antitumor activity of JSKN022 in patients with advanced malignant solid tumors who have failed standard therapies, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). About JSKN022JSKN022 is a first-in-class ADC targeting both PD-L1 and integrin αvβ6. Based on independently developed Envafolimab, Alphamab integrates immuno-oncology (IO) mechanisms with ADC approaches. This novel drug molecule utilizes glycan-specific conjugation technology to enhance both stability and homogeneity. The topoisomerase I inhibitor T01 is site-specifically conjugated to antibodies via a cleavable linker, enhancing therapeutic efficacy. JSKN022 is expected to provide a novel therapeutic option for cancers that are refractory or resistant to PD-1/PD-L1 inhibitors. The IND application for the first-in-human clinical study of JSKN022 for the treatment of advanced malignant solid tumors has been accepted by CDE. About Alphamab OncologyAlphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies. The Company has one product approved for marketing (Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide. View original content: SOURCE Alphamab Oncology Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Old trees and ageing farmers worsen outlook for top palm oil exporters
By Ashley Tang, Naveen Thukral and Bernadette Christina PONTIAN, Malaysia (Reuters) -Malaysian farmer Suratmen Mosman faces a dilemma that threatens to sap supply from the world's top palm oil exporters and drive up prices of the vegetable oil essential to billions of consumers worldwide in the next five years. The ageing trees on his plantation 300 km (185 miles) south of Kuala Lumpur are bearing less fruit, but the 85-year-old is holding off replacing them as he doesn't want to lose income while waiting the three to five years it takes for new trees to start yielding a crop and the years beyond that it will take for them to reach peak production. Government subsidies to encourage replanting are not as high as they once were and he needs to support his family. Used mostly as a cooking oil, but also to make cakes, cosmetics and cleaning products, palm oil makes up more than half of the world's vegetable oil supply and 85% of the crude product comes from Malaysia and Indonesia. But after decades of soaring output, the market is now at a tipping point as combined exports from the two producers are set to slow sharply, the result of stagnating production and efforts by Indonesia to divert more palm oil into the production of biodiesel. While financial markets have factored in the slowdown, there is growing evidence that plantations run by smallholders like Suratmen may be in worse condition than previously thought as ageing and lower-yielding trees are not replaced, which will add to the decline. Smallholders make up 40% of the plantations across Malaysia and Indonesia, so they play a vital role in the supply chain. Supplies to global markets from Indonesia and Malaysia could fall as much as 20% over the next five years, according to Reuters' calculations based on government and industry projections, some previously unpublished. Future output from smallholders may well be over-estimated because the condition of trees and the rate of planting new trees is worse than estimates by the governments in Kuala Lumpur and Jakarta, according to veteran industry figures Dorab Mistry and M.R. Chandran. That view is backed up by Reuters interviews with more than a dozen farmers and officials in Malaysia. And other previously unpublished data shows the acreage of plantations where trees are older than 20 years - a point at which they are considered beyond their peak - is growing fast. Mistry, a director of Indian consumer goods firm Godrej International and a long-term palm oil analyst who has been in the industry for more than 40 years, and Chandran, the former head of the Malaysian Palm Oil Association, estimated that more than half of the trees on Malaysian smallholder plantations are well past peak production. The estimate is significantly higher than Malaysian government data, which shows 37% of smallholder plantations are past their peak yielding phase. "Palm oil supplies are getting tighter," said Mistry, who bases his estimate on site visits to plantations, data analysis, and engagement with producers, traders, and other key industry players. "This is not just a problem in Malaysia but also in Indonesia. Though Indonesia's industry is younger, it will face the same problems in the next five years," he said. In Indonesia, just 10% of a 2016 government target to replant 2.5 million hectares (9,653 square miles) by 2025 had been met as of last October, publicly available government data showed. As a result, over one-third of oil palms among both smallholders and industrial plantations are either at or past their most productive years. Acreage for trees older than 21 years is set to rise 11% next year in Indonesia, according to previously unreleased data from state research firm Riset Perkebunan Nusantara (RPN). Reluctance in Malaysia and Indonesia to replace old trees, plus Indonesia's increased biodiesel mandates, point to a sharp drop in palm oil exports in the coming five years. Calculations based on Malaysian and Indonesia palm oil body estimates suggest combined exports are likely to drop to about 37 million metric tons by 2030, down by a fifth since 2024. Indonesia is likely to have around 20 million tons available for export, down by nearly a third from last year, according to forecasts from RPN and the Indonesia Palm Oil Association (GAPKI). There are no official forecasts for Malaysian palm exports by 2030, but Mistry said expectations are now that they will remain steady or decline slightly, reflecting a lack of consistent replanting and in contrast to earlier estimates of modest annual increases. Indonesia's Ministry of Agriculture did not respond to requests for comment on the estimates for output and exports to drop. State-run industry regulator the Malaysian Palm Oil Board said it did not agree with the assessment that over 50% of smallholders' oil palm trees are beyond peak yielding age. "According to MPOB's 2024 data, only 36.2% of smallholders' oil palm trees are over 18 years old, and many smallholders have already begun replanting with government support," the board said in a response to questions from Reuters. To ease replanting costs, the government offers a 50% grant and 50% loan, it added. "The government values smallholders' contributions and continues to refine support schemes based on ongoing feedback to ensure long-term sustainability and inclusivity," it said. DEMAND RISING Industry projections indicate global demand will rise by 50 million tons by 2050, requiring minimum annual supply growth of 2%, Chandran said. However, he estimates production is on track to grow at just 1.5% annually, he said, based on ageing trees and slow replanting rates in both countries. The contrast to palm's earlier growth is stark. Palm doubled its share of the global vegetable oils market to 30.6% in the three decades to 1995, with Indonesian production growing an annual 8.1% and Malaysian output rising 3% over the same period. "There will be growing tensions between rising global demand and the challenge of expanding production sustainably," said Chandran, who is also chairman of IRGA, an agritech firm specialising in data analysis and field research. Already, strained palm oil supplies are pushing up costs for alternatives including soybean, rapeseed and sunflower oil. Last year, crude palm oil traded at a $39/ton premium to soybean oil compared to a $160 discount in 2023, according to the Malaysian Palm Oil Board. Top buyer India's annual palm oil imports are set to drop below other edible oils for the first time this year as rising palm costs push refiners toward alternatives. RELUCTANT REPLANTERS Interviews with 11 small-scale Malaysian farmers found most were reluctant to replant as mature trees are their main income source amid two-year high prices. "I did not replant my trees as I do not have any other sources of income," Suratmen said, standing among his five acres of oil palms in Johor state's Pontian district. Some of his newer trees were planted on unstable peatland and lean at angles. "My replanting efforts are limited to replacing fallen trees or planting new ones in between existing trees," he said. Most smallholders converted rubber plantations to palm in the early 1990s and 2000s, so their trees have now reached the 25-year mark and are due for replanting, said National Association of Smallholders Malaysia president Adzmi Hassan. The challenge is compounded by mostly ageing landowners, many of whose children have moved to cities, leaving planters without the labour or physical capacity to replant. "You have to consider the plantation cost, the work to replant, and there are many independent smallholders who do not want to be tied down to a bank debt," said Mohd Sharul Haizam Shafei, 42, who owns 50 acres of plantation in Banting. In Malaysia, the replanting rate averaged about 2% over the past five years, half the government's 4% target, according to Malaysian Palm Oil Board data. REPLANTING COSTS DETER FARMERS While the Malaysian government provides a grant for half of replanting expenses, many smallholders are unwilling to take on debt to cover the rest, said Adzmi from the smallholders' association. He is lobbying the government to fully subsidise replanting, as it did before 2019, but that is seen as unlikely as the government is cutting subsidies elsewhere, including for fuel. Indonesia last year doubled replanting funding for smallholders, but Gulat Manurung, chairman of planters' group APKASINDO, said farmers struggle to access the funds due to land legality issues and complicated terms. With ageing trees, fresh fruit bunch yields for smallholders in Indonesia last year averaged 9.6 tons per hectare, Indonesia Palm Oil Board data showed, less than half the yields produced at larger state-owned and private plantations. The industry is in a bind to boost output as Malaysia caps total planted area while Indonesia, under pressure from the European Union and environmental groups, has a moratorium on new forest clearing for palm plantations. Suratmen, the farmer in Pontian, said without a full subsidy, he's not replanting. "Waiting for new trees to mature and produce fruit takes too long. We cannot support our families during those years without income from the trees," he said.
Bloomberg
22 minutes ago
- Bloomberg
Trump Tariff Shock Poised to Deepen Rupee's Underperformance
India's rupee is poised to remain one of Asia's worst performers in the second half of the year, with US tariffs adding pressure to an already fragile economic recovery, analysts say. Analysts at Deutsche Bank AG and Barclays Plc expect the currency to drop to new record lows by the year-end amid muted foreign inflows and headwinds from US tariffs. Meanwhile, the Chinese yuan, Indonesian rupiah, Malaysian ringgit and Philippine peso are projected to gain, according to estimates compiled by Bloomberg.
